相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki et al.
MOLECULAR CANCER RESEARCH (2017)
ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
Christabel Wilson et al.
SCIENTIFIC REPORTS (2017)
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
Elisabet Cuyas et al.
CELL CYCLE (2016)
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK plus tumors
Amit Dipak Amin et al.
ONCOTARGET (2016)
The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
Abdulraheem Alshareef et al.
SCIENTIFIC REPORTS (2016)
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
Annie Guerin et al.
CANCER EPIDEMIOLOGY (2015)
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni et al.
ONCOTARGET (2015)
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
Diletta Fontana et al.
CANCER MEDICINE (2015)
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Hideko Isozaki et al.
CANCERS (2015)
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
M. Ceccon et al.
MOLECULAR CANCER RESEARCH (2015)
ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
Federica Lovisa et al.
PLOS ONE (2015)
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
Cheng Ji et al.
CANCER BIOLOGY & THERAPY (2014)
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Daria Zdzalik et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
Gouji Toyokawa et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer
Xiaolong Qi et al.
LUNG CANCER (2014)
Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation
Cesar A. Perez et al.
LUNG CANCER (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
Suraj Konnath George et al.
ONCOTARGET (2014)
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
High Anaplastic Lymphoma Kinase Immunohistochemical Staining in Neuroblastoma and Ganglioneuroblastoma Is an Independent Predictor of Poor Outcome
Floor A. M. Duijkers et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma
Jingdong Zhang et al.
CELLULAR SIGNALLING (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
Junko Tanizaki et al.
CLINICAL CANCER RESEARCH (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Avaniyapuram Kannan Murugan et al.
CANCER RESEARCH (2011)
Anaplastic lymphoma kinase in human cancer
Antonella Barreca et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
Ping Shi et al.
BLOOD (2009)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
SD Turner et al.
LEUKEMIA (2005)
Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor
T Criswell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Fusion of ALK to the ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
ZG Ma et al.
GENES CHROMOSOMES & CANCER (2003)
Translocations involving anaplastic lymphoma kinase (ALK)
J Duyster et al.
ONCOGENE (2001)
Mechanism of STAT3 activation by insulin-like growth factor I receptor
CS Zong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
